Fonte: Journal of molecular histology. Unidades: FM, FMVZ
Assuntos: MODELOS ANIMAIS, NEOPLASIAS HEPÁTICAS, INIBIDORES DE ENZIMAS
ABNT
NASSAR-REIS, Joao Pedro et al. P53 and VEGF are promising biomarkers for sorafenib efficacy in an experimental model of NASH-related HCC. Journal of molecular histology, v. 54, n. 5, p. 473-488, 2023Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/57413. Acesso em: 26 ago. 2024.APA
Nassar-Reis, J. P., Umeta, P. F., Stefano, J. T., Longatto Filho, A., Carrilho, F. J., Alves, V. A. F., et al. (2023). P53 and VEGF are promising biomarkers for sorafenib efficacy in an experimental model of NASH-related HCC. Journal of molecular histology, 54( 5), 473-488. doi:10.1007/s10735-023-10142-9NLM
Nassar-Reis JP, Umeta PF, Stefano JT, Longatto Filho A, Carrilho FJ, Alves VAF, Cogliati B, Oliveira CPMS de. P53 and VEGF are promising biomarkers for sorafenib efficacy in an experimental model of NASH-related HCC [Internet]. Journal of molecular histology. 2023 ; 54( 5): 473-488.[citado 2024 ago. 26 ] Available from: https://observatorio.fm.usp.br/handle/OPI/57413Vancouver
Nassar-Reis JP, Umeta PF, Stefano JT, Longatto Filho A, Carrilho FJ, Alves VAF, Cogliati B, Oliveira CPMS de. P53 and VEGF are promising biomarkers for sorafenib efficacy in an experimental model of NASH-related HCC [Internet]. Journal of molecular histology. 2023 ; 54( 5): 473-488.[citado 2024 ago. 26 ] Available from: https://observatorio.fm.usp.br/handle/OPI/57413